Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313508 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccination During Lymphoid Reconstruction
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00313508 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 18 participants.
The verdict
NCT00313508, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms. The purpose of this study is to find out what side effects are caused in this study and whether Fludarabine with the dendritic cell vaccine (DC vaccine) can increase the ability of the immune system to recognize melanoma.
Interventions
- DRUG Fludarabine
- BIOLOGICAL Autologous Dendritic Cells (DC)
- BIOLOGICAL Autologous Lymphocyte Infusion (ALI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313508
The ClinicalTrials.gov registry entry for NCT00313508 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00313508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313508 about?
NCT00313508 is a clinical study titled "Dendritic Cell Vaccination During Lymphoid Reconstruction". This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms. The purpose of this study is to find out what side effects are caused in this study and whether Fludarabine with the dendritic cell vaccine (DC vaccine) can increas...
What is the current status of trial NCT00313508?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00313508?
The interventions under investigation include: Fludarabine (DRUG), Autologous Dendritic Cells (DC) (BIOLOGICAL), Autologous Lymphocyte Infusion (ALI) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00313508?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.